Clinical Focus


  • Pediatric Hematology-Oncology

Academic Appointments


Professional Education


  • Board Certification: American Board of Pediatrics, Hospice and Palliative Medicine (2016)
  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2011)
  • Fellowship: Nationwide Children's Hospital (2009) OH
  • Board Certification: American Board of Pediatrics, Pediatrics (2007)
  • Residency: University of Illinois at Chicago Pediatric Residency (2006) IL
  • Medical Education: Universidad Francisco Marroqu?n (2001) Guatemala

All Publications


  • A Pheochromocytoma Mimicker: Mercury Poisoning. Pediatric blood & cancer Pacaja-Rojas, A. F., Fernandez, K. S. 2025: e31883

    View details for DOI 10.1002/pbc.31883

    View details for PubMedID 40563203

  • Frequency and phenotype of aquaporin-4-IgG and coexistent autoimmune encephalitis (neuronal and glial) antibody biomarkers: a laboratory-based analysis of over 6,000 tests Cacciaguerra, L., Yang, B., Agnihotri, S. P., Ahsan, N., Fernandez, K. S., Massey, R. L., McLeod, E., Meador, W., Mitchell, W. G., Nicholas, J., Lin, M., Quek, A., Shoemaker, T., Sieloff, K., Sui, V., Waubant, E., Flanagan, E., McKeon, A., Pittock, S., Kunchok, A. SAGE PUBLICATIONS LTD. 2023: 406-407
  • Paraneoplastic juvenile idiopathic arthritis as a manifestation of a benign teratoma in a 5-year-old female. Pediatric blood & cancer Kamal, S., Sukumaran, S., LePhong, C., Fernandez, K. S. 2023: e30603

    View details for DOI 10.1002/pbc.30603

    View details for PubMedID 37501609

  • Alveolar soft part sarcoma: Prolonged response to immune checkpoint inhibitors. Pediatric blood & cancer Titapiwatanakun, R., Farrell, C., Fernandez, K. S. 2023: e30414

    View details for DOI 10.1002/pbc.30414

    View details for PubMedID 37170856

  • When bone pain and bleeding mean more than leukemia: The case of nutritional deficiencies. Pediatric blood & cancer Emamian, A., Abugroun, I., Laningham, F., Fernandez, K. S. 2023: e30272

    View details for DOI 10.1002/pbc.30272

    View details for PubMedID 36912401

  • Retroperitoneal Ewing sarcoma requiring nephrectomy for local control JOURNAL OF PEDIATRIC SURGERY CASE REPORTS Qumsiyeh, Y., Fernandez, K. S., Fata, C., Barthel, E. R. 2021; 71
  • Ovarian teratoma masquerading as encephalitis in an adolescent. Pediatric blood & cancer Emamian, A., Santi, D., Appu, M., Tcheng, W., Fernandez, K. S. 2021: e29027

    View details for DOI 10.1002/pbc.29027

    View details for PubMedID 33773057

  • Simultaneous occurrence of Hodgkin lymphoma and tuberculosis in children and adolescents PEDIATRIC BLOOD & CANCER Obando, P., Veron, D. A., Castellanos, M., Fernandez, K. S. 2020; 67 (8): e28405

    View details for DOI 10.1002/pbc.28405

    View details for Web of Science ID 000535621100001

    View details for PubMedID 32459373

  • Rituximab and intense chemotherapy in a patient with defective cell mediated immunity due to cartilage-hair hypoplasia and Burkitt lymphoma PEDIATRIC BLOOD & CANCER Speckhart, B. A., Bugaieski, E., Antony, R., Fernandez, K. S. 2020; 67 (7): e28259

    View details for DOI 10.1002/pbc.28259

    View details for Web of Science ID 000531867200001

    View details for PubMedID 32400949

  • Sirolimus for the treatment of juvenile nasopharyngeal angiofibroma PEDIATRIC BLOOD & CANCER Fernandez, K. S., de Alarcon, A., Adams, D. M., Hammill, A. M. 2020; 67 (4): e28162

    Abstract

    Juvenile nasopharyngeal angiofibroma (JNA) is a pathologically benign yet locally aggressive and destructive tumor that develops in the choana and nasopharynx. Historical treatment of JNA has included embolization, surgical resection, and radiation. Here, we describe three patients who received therapy with the mTOR inhibitor sirolimus with improvement in clinical symptoms, imaging, and overall well-being.

    View details for DOI 10.1002/pbc.28162

    View details for Web of Science ID 000506527000001

    View details for PubMedID 31925925

  • Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18y) With Early Relapse Hodgkin Lymphoma. Journal of pediatric hematology/oncology Fernandez, K. S., Mavers, M., Marks, L. J., Agarwal, R. 2019

    Abstract

    We describe 6 pediatric patients (12 to 18y) with relapsed or refractory Hodgkin lymphoma treated with consolidative Brentuximab vedotin (Bv) following reinduction chemotherapy and autologous stem cell transplantation. The progression-free survival after autologous stem cell transplantation was 12, 18, 22, 24, 30, and 30 months. Most patients tolerated Bv well although 2 patients developed grade 3 neuropathy that prevent them from completing the scheduled 16 doses of Bv. Consolidative Bv in children and adolescents, as currently recommended for adult patients with early relapsed or refractory Hodgkin lymphoma, is feasible but with some significant toxicities.

    View details for DOI 10.1097/MPH.0000000000001703

    View details for PubMedID 31876780

  • Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma Titapiwatanakun, R., Batth, S., Baker, K., Tcheng, W., Fernandez, K. S. AMER SOC HEMATOLOGY. 2019
  • Feasibility of brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in children and adolescents (< 18 years) with early relapse Hodgkin lymphoma. Fernandez, K. S., Mavers, M., Chang-Halpenny, C. N., Titapiwatanakun, R., Baker, K., Pugmire, B., Tcheng, W., Agarwal-Hashmi, R. AMER SOC CLINICAL ONCOLOGY. 2019